HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management
- PMID: 17854732
- DOI: 10.1016/j.drugpo.2007.01.011
HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management
Abstract
Issues: HIV/hepatitis coinfection in Europe; WHO European clinical protocols on the management of people coinfected with HIV/AIDS and hepatitis B or C (HBV or HCV); stakeholder recommendations for better HCV services.
Introduction: The increasing availability of highly active antiretroviral therapy throughout Europe and central Asia has changed comorbidity and mortality patterns among people living with HIV/AIDS (PLWHA) as liver disease has increasingly replaced AIDS as the cause of death in PLWHA in western European countries. The average prevalence of HCV among PLWHA is 40 per cent, and much higher in countries where the HIV epidemic is driven by injecting drug use. Access to hepatitis treatment for PLWHA and IDUs is still very limited in Europe due to a lack of clear clinical management guidelines for HIV/hepatitis coinfections, high costs and a national failure to recognise hepatitis as a critical health issue.
Description: In October 2006, the WHO Regional Office for Europe issued protocols for the clinical management of HIV/HCV and HIV/HBV coinfections. They include diagnostic algorithms adjusted for resource availability, and guidelines for the management of patients who do not yet need treatment, those who need only hepatitis or only HIV/AIDS treatment, and those who need both. Though the protocols should provide practical guidelines for physicians and assist in the development of national treatment standards, there is still a need for targeted prevention, treatment and care interventions. To expand access to hepatitis prevention and treatment, public awareness needs to be raised and national political leaders need to address hepatitis as a public health issue. Effective public health measures include price reductions for anti-hepatitis drugs; targeted testing, counselling and prevention activities; increased access to hepatitis B and C treatment and to HBV vaccination for the populations most at risk.
Similar articles
-
Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.Int J Drug Policy. 2007 Oct;18(5):417-25. doi: 10.1016/j.drugpo.2007.01.013. Epub 2007 Feb 20. Int J Drug Policy. 2007. PMID: 17854731 Review.
-
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.HIV Med. 2008 Feb;9(2):82-8. doi: 10.1111/j.1468-1293.2007.00535.x. HIV Med. 2008. PMID: 18257771
-
Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.Eur J Gen Pract. 2007;13(1):5-12. doi: 10.1080/14017430601049365. Eur J Gen Pract. 2007. PMID: 17366287
-
Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients.Trop Gastroenterol. 2008 Jul-Sep;29(3):136-47. Trop Gastroenterol. 2008. PMID: 19115605 Review.
-
Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database.J Gastroenterol Hepatol. 2007 Sep;22(9):1510-8. doi: 10.1111/j.1440-1746.2007.05062.x. Epub 2007 Jul 20. J Gastroenterol Hepatol. 2007. PMID: 17645479
Cited by
-
Co-infections of tuberculosis, hepatitis B or C viruses in a cohort of people living with HIV/AIDS in China: predictors and sequelae.AIDS Care. 2017 Aug;29(8):974-977. doi: 10.1080/09540121.2016.1271388. Epub 2016 Dec 21. AIDS Care. 2017. PMID: 27998171 Free PMC article.
-
Prevalence of Viral Hepatitis B, C, and D in Kazakhstan.ScientificWorldJournal. 2022 Apr 22;2022:9102565. doi: 10.1155/2022/9102565. eCollection 2022. ScientificWorldJournal. 2022. PMID: 35492864 Free PMC article.
-
Hepatitis B and C among patients infected with human immunodeficiency virus in Isfahan, Iran: seroprevalence and associated factors.Hepat Mon. 2010 Summer;10(3):188-92. Epub 2010 Sep 1. Hepat Mon. 2010. PMID: 22308138 Free PMC article.
-
Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors.Harm Reduct J. 2013 May 7;10:7. doi: 10.1186/1477-7517-10-7. Harm Reduct J. 2013. PMID: 23651646 Free PMC article. Review.
-
Hepatitis-C multimedia prevention program in poor Hispanic HIV-infected injecting drug users: six months after intervention.J Health Care Poor Underserved. 2013 Nov;24(4 Suppl):29-37. doi: 10.1353/hpu.2014.0015. J Health Care Poor Underserved. 2013. PMID: 24241258 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical